Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Opus Genetics, Inc.IRD · Entity 5892 | Director | September 08, 2026 | September 08, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · President, Interim CFO | May 31, 2024 | May 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Opus Genetics, Inc.
Report date September 08, 2026 · Filed September 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,800,111 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 784,314 · Balance 2,800,111 F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. |
| Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.15 · Expires 2030-03-25 | Direct | 0 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 784,314 · Balance 0 F3: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. |
| Common StockSEC Table I · non-derivative | IndirectBy Garret Gallagher - Custodian UTMA/UGMA | 83,000 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 83,000 F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. F2: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein.
F2: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
F3: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day.
Zentalis Pharmaceuticals, Inc.
Report date May 31, 2024 · Filed May 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 633,680 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Sale · Disposed 9,597 · Balance 633,680 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 8, 2026 20:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Exercise / conversionWarrant (right to buy) · Derivative | 784,314 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001140361-26-035913 · form4.xml · derivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 784,314 shares Expires 2030-03-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The Warrant was immediately exercisable upon its acquisition on March 24, 2025, subject to the Issuer's right to call the Warrant at any time beginning 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's Common Stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. Read SEC document |
| September 08, 2026 Filed Sep 8, 2026 20:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | Exercise / conversionCommon Stock | 784,314 | $1.15 | $901,961.10 |
DisclosureSEC source: 0001140361-26-035913 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,800,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: In conjunction with the exercise of the Warrant reported herein, the Reporting Person entered into a Lock-Up Agreement with the Issuer dated September 6, 2026 (the "Lock-Up Agreement"). Pursuant to the Lock-Up Agreement, among other terms, the Reporting Person agreed that, without the prior written consent of the Issuer, during the period beginning on September 6, 2026 and ending at the close of business 180 days after the issuance of the shares of Common Stock underlying the Warrant, the Reporting Person will not transfer or dispose of, directly or indirectly, any shares of Common Stock, or any securities convertible into or exercisable or exchangeable for Common Stock (including, without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the Reporting Person and securities which may be issued upon exercise of a stock option or warrant), as further described in the Lock-Up Agreement and subject to certain exclusions described therein. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 20:30 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 24,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-001785 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,015,797 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:13 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 67,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-26-000088 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,991,430 F1 · shares: Represents a grant of restricted stock units which vest on December 29, 2026, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| December 31, 2025 Filed Dec 31, 2025 21:33 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-004511 · form4.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,924,430 F4 · shares: Represents a grant of restricted stock units ("RSUs") which vest on December 29, 2026, subject to the Reporting Person's continuing service through the vesting date. F5 · shares: On December 31, 2025, the Issuer's Board of Directors also approved a grant to the Reporting Person, effective January 6, 2026, of an additional 67,000 RSUs which vest on December 29, 2026, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:33 UTC | Opus Genetics, Inc. IRD · Entity 5892 | PurchaseCommon Stock | 83,000 | $1.97 | $163,418.70 |
DisclosureSEC source: 0000905148-25-004511 · form4.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Garret Gallagher - Custodian UTMA/UGMA Disclosed balance after: 83,000 F2 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.9476 to $1.98, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F3 · ownership.nature: These securities are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Read SEC document |
| December 29, 2025 Filed Dec 31, 2025 21:33 UTC | Opus Genetics, Inc. IRD · Entity 5892 | PurchaseCommon Stock | 81,000 | $1.98 | $160,274.70 |
DisclosureSEC source: 0000905148-25-004511 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,891,430 F1 · price: The price in column 4 represents the weighted average price. The shares were purchased in multiple transactions at prices ranging from $1.945 to $1.98, inclusive. The Reporting Person undertakes to provide the issuer, any securityholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| August 25, 2025 Filed Aug 27, 2025 20:15 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 869,565 | $1.15 | $999,999.75 |
DisclosureSEC source: 0000905148-25-003152 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,810,430 Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 79,592 | $0.00 Strike: $0.95 | $0.00 |
DisclosureSEC source: 0000905148-25-001427 · form4.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,592 Underlying: Common Stock · 79,592 shares Expires 2035-04-29 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| April 30, 2025 Filed May 2, 2025 21:05 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 79,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-001427 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 940,865 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:08 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantWarrants (right to buy) · Derivative | 784,314 | Not disclosed Strike: $1.15 | Not disclosed |
DisclosureSEC source: 0000905148-25-001006 · form4.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,314 Underlying: Common Stock · 784,314 shares Expires 2030-03-24 F1 · kind: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. F1 · price: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. F2 · derivative.exercise_date: These warrants are immediately exercisable and may be called by the Issuer at any time starting with 30 days following the release of the Issuer's OPGx-BEST1 DUO-1001 Cohort 1 data upon achievement of (i) a volume weighted average price of the Issuer's common stock for 30 consecutive trading days of over $1.725 per share and (ii) the trading average daily volume for such 30 day period exceeding $150,000 per trading day. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 20:08 UTC | Opus Genetics, Inc. IRD · Entity 5892 | GrantCommon Stock | 784,314 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000905148-25-001006 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 861,361 F1 · kind: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. F1 · price: Each share of common stock was purchased together with a warrant to purchase one share of common stock in a transaction that is exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3(d) thereunder. The combined purchase price of each pair of common stock and warrant was $1.275. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:27 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (Right to Buy) · Derivative | 35,181 | $0.00 Strike: $1.72 | $0.00 |
DisclosureSEC source: 0000905148-24-001711 · form4.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,181 Underlying: Common Stock · 35,181 shares Expires 2034-06-10 F2 · derivative.exercise_date: The option will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| June 11, 2024 Filed Jun 13, 2024 21:27 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 41,143 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-24-001711 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,047 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| May 31, 2024 Filed May 31, 2024 22:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,597 | $11.98 | $114,972.06 |
DisclosureSEC source: 0001725160-24-000127 · wk-form4_1717194425.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President, Interim CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,680 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 01:21 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,173 | $11.44 | $13,419.12 |
DisclosureSEC source: 0001725160-24-000041 · wk-form4_1707787292.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 643,277 F1 · kind: Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 11,552 | $11.54 | $133,310.08 |
DisclosureSEC source: 0001725160-24-000030 · wk-form4_1707178402.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 644,450 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 192,500 | $0.00 Strike: $11.69 | $0.00 |
DisclosureSEC source: 0001725160-24-000030 · wk-form4_1707178402.xml · derivative · entry 3 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2034-01-31 F4 · derivative.exercise_date: The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| February 01, 2024 Filed Feb 6, 2024 00:13 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 192,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-24-000030 · wk-form4_1707178402.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 656,002 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:48 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option · Derivative | 9,639 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0001140361-23-029020 · form4.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,639 Underlying: Common Stock · 9,639 shares Expires 2033-06-05 F2 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| June 06, 2023 Filed Jun 8, 2023 22:48 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantCommon Stock | 10,976 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-029020 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,904 F1 · shares: Represents a grant of restricted stock units which vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 01:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 18,526 | $26.21 | $485,527.56 |
DisclosureSEC source: 0001725160-23-000125 · wk-form4_1685581824.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 463,502 F2 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.91 to $26.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 31, 2023 Filed Jun 1, 2023 01:10 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,242 | $26.40 | $243,978.63 |
DisclosureSEC source: 0001725160-23-000125 · wk-form4_1685581824.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 482,028 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. Read SEC document |
| February 14, 2023 Filed Feb 15, 2023 00:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,501 | $19.96 | $169,706.31 |
DisclosureSEC source: 0001725160-23-000033 · wf-form4_167641974905249.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 491,270 F3 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.73 to $20.30. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 00:09 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,332 | $20.42 | $68,054.10 |
DisclosureSEC source: 0001725160-23-000033 · wf-form4_167641974905249.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 499,771 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.79 to $20.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 00:36 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 572 | $23.04 | $13,176.08 |
DisclosureSEC source: 0001725160-23-000022 · wf-form4_167573016060449.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,103 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.88 to $23.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 06, 2023 Filed Feb 7, 2023 00:36 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,428 | $22.22 | $209,502.42 |
DisclosureSEC source: 0001725160-23-000022 · wf-form4_167573016060449.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 503,675 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $21.77 to $22.76. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 00:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 233,908 | $0.00 Strike: $23.65 | $0.00 |
DisclosureSEC source: 0001725160-23-000019 · wf-form4_167529650576789.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 233,908 Underlying: Common Stock · 233,908 shares Expires 2033-01-31 F2 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 00:08 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 161,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-23-000019 · wf-form4_167529650576789.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,103 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 22:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 500 | $24.87 | $12,433.60 |
DisclosureSEC source: 0001725160-23-000008 · wf-form4_167408008586817.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,011 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.78 to $24.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 17, 2023 Filed Jan 18, 2023 22:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,500 | $24.11 | $229,081.10 |
DisclosureSEC source: 0001725160-23-000008 · wf-form4_167408008586817.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,511 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.76 to $24.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 300 | $21.46 | $6,437.01 |
DisclosureSEC source: 0001725160-23-000002 · wf-form4_167296417221057.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,011 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $21.44 to $21.47. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 00:16 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,700 | $21.01 | $203,791.18 |
DisclosureSEC source: 0001725160-23-000002 · wf-form4_167296417221057.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,311 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $20.39 to $21.35. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 14:00 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | OtherSeries B Warrant (right to buy) · Derivative | 1,574 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-23-000746 · form4.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,574 shares Expires 2023-01-05 F1 · derivative.expiration_date: The expiration date of the Series B Warrants occurred on the later of (x) the Reservation Date (as defined in the Series B Warrants) and (y) the date on which the Series B Warrants has been exercised in full. Read SEC document |
| January 04, 2023 Filed Jan 6, 2023 14:00 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | OtherCommon Stock | 1,574 | $0.00 | $0.16 |
DisclosureSEC source: 0001140361-23-000746 · form4.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,928 Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 00:50 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 900 | $23.48 | $21,131.10 |
DisclosureSEC source: 0001725160-22-000202 · wf-form4_166855982730331.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,011 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.21 to $23.57. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 15, 2022 Filed Nov 16, 2022 00:50 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 11,600 | $22.72 | $263,552.00 |
DisclosureSEC source: 0001725160-22-000202 · wf-form4_166855982730331.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 372,911 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.20 to $23.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,374 | $23.56 | $291,542.58 |
DisclosureSEC source: 0001725160-22-000194 · wf-form4_166795791845543.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,511 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.18 to $23.94. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 157 | $24.24 | $3,805.27 |
DisclosureSEC source: 0001725160-22-000194 · wf-form4_166795791845543.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 396,885 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.22 to $24.31. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2022 Filed Nov 9, 2022 01:38 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,343 | $23.66 | $292,055.13 |
DisclosureSEC source: 0001725160-22-000194 · wf-form4_166795791845543.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 397,042 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.16 to $24.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 17, 2022 Filed Oct 18, 2022 01:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,500 | $23.51 | $293,878.75 |
DisclosureSEC source: 0001725160-22-000184 · wf-form4_166605490632481.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,385 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.00 to $23.96. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 06, 2022 Filed Oct 7, 2022 20:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,000 | $22.62 | $226,180.00 |
DisclosureSEC source: 0001725160-22-000182 · wf-form4_166517520562805.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 421,885 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.20 to $23.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,496 | $22.83 | $125,478.08 |
DisclosureSEC source: 0001725160-22-000182 · wf-form4_166517520562805.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,885 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $22.47 to $23.17. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 05, 2022 Filed Oct 7, 2022 20:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,004 | $21.92 | $153,528.38 |
DisclosureSEC source: 0001725160-22-000182 · wf-form4_166517520562805.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 437,381 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $21.43 to $22.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2022 Filed Sep 17, 2022 00:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,134 | $24.99 | $28,338.43 |
DisclosureSEC source: 0001725160-22-000167 · wf-form4_166337433049948.xml · nonDerivative · entry 4 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444,385 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.84 to $25.12. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2022 Filed Sep 17, 2022 00:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,866 | $24.38 | $216,158.40 |
DisclosureSEC source: 0001725160-22-000167 · wf-form4_166337433049948.xml · nonDerivative · entry 3 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 445,519 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $23.83 to $24.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 17, 2022 00:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,074 | $25.59 | $104,239.81 |
DisclosureSEC source: 0001725160-22-000167 · wf-form4_166337433049948.xml · nonDerivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 454,385 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.39 to $25.95. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 17, 2022 00:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 8,426 | $25.10 | $211,517.04 |
DisclosureSEC source: 0001725160-22-000167 · wf-form4_166337433049948.xml · nonDerivative · entry 1 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 458,459 F1 · kind: The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.39 to $25.38. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:01 UTC | Opus Genetics, Inc. OCUP · Entity 5892 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $1.93 | $0.00 |
DisclosureSEC source: 0001140361-22-023051 · form4.xml · derivative · entry 1 Gallagher Cam · CIK 0001557832 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-12 F1 · derivative.exercise_date: Will vest upon the earlier of the one (1) year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders occurring after the grant date, subject to the Reporting Person's continuing service through the vesting date. Read SEC document |
| May 30, 2022 Filed May 31, 2022 20:06 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 333,218 | $0.00 Strike: $24.75 | $0.00 |
DisclosureSEC source: 0001725160-22-000116 · wf-form4_165402754252137.xml · derivative · entry 2 Gallagher Cam · CIK 0001557832 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,218 Underlying: Common Stock · 333,218 shares Expires 2032-05-29 F2 · derivative.exercise_date: The options vest and become exercisable as to 25% of the total number of shares underlying the option on May 30, 2023 and as to the remaining 75% in 36 substantially equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.